Key Financial Figures

  • Total Revenue from Operations: ₹5,384.02 lakhs
  • Net Profit before Depreciation & Taxation: ₹191.56 lakhs (Previous Year: ₹294.51 lakhs)
  • Depreciation: ₹399.88 lakhs (Previous Year: ₹425.46 lakhs)
  • Provision for Deferred Taxation: ₹10.42 lakhs (Previous Year: ₹15.41 lakhs)
  • Provision for Taxation/Written Off: ₹22.54 lakhs (Previous Year: Nil)
  • Net Loss: ₹220.46 lakhs (Previous Year: Loss of ₹146.37 lakhs)
  • Balance brought forward from last year: ₹2,533.06 lakhs
  • Profit/Loss carried to Balance Sheet: ₹2,312.60 lakhs
  • Paid-up Equity Share Capital: ₹364.83 lakhs (36,48,300 equity shares of ₹10 each)
  • Total Assets: ₹7,978.70 lakhs
  • Inventories: ₹4,064.62 lakhs (50.94% of total assets)
  • Trade Receivables: ₹1,828.19 lakhs
  • Cash and Cash Equivalents: ₹20.17 lakhs
  • Borrowings (Current): ₹1,070.90 lakhs (secured by hypothecation of stock and book debts)
  • Trade Payables: ₹748.23 lakhs (including ₹605.37 lakhs to micro and small enterprises)

Dates of Significance

  • Financial Year: April 1, 2025 to March 31, 2026
  • AGM Date: September 28, 2026 (through Video Conferencing)
  • Book Closure: September 22, 2026 to September 28, 2026 (both days inclusive)
  • Board Meetings Held: May 28, 2025; June 21, 2025; August 12, 2025; November 13, 2025; February 12, 2026
  • Annual Report Submission Date: September 1, 2026

Parties Involved

  • Stock Exchange: BSE Limited
  • Bankers: Canara Bank Ltd
  • Statutory Auditors: Mahesh Chandra & Associates (Firm Registration No. 112334W)
  • Internal Auditors: Utsav Shah & Associates
  • Secretarial Auditors: HSPN & Associates LLP
  • Registrars & Share Transfer Agents: Purva Sharegistry (India) Pvt. Ltd (SEBI registration no.: INR000001112)
  • Directors:
  • Vijay Majrekar (Managing Director/CEO, DIN: 00804808)
  • Anuradha Kashikar (Executive Director/CFO, DIN: 00804831)
  • Devraj T. Poojary (Executive Director, DIN: 02041726)
  • Neel M. Vora (Independent Director, DIN: 07699873)
  • Ridhima B. Limaye (Independent Director, DIN: 10256393)
  • Akash S. Modi (Independent Director, DIN: 08698016)
  • Anuj V. Shah (Independent Director, DIN: 10256390)

Operational and Strategic Highlights

  • Business Operations: Medical device company engaged in manufacturing surgical sutures, other medical devices, and started manufacturing of surgical threads
  • Manufacturing Facilities: Located at F-29, B-17, F-22, F-23, F-24, MIDC, Murbad, Thane, Maharashtra and Village Dhavale, Ambernath, Thane, Maharashtra
  • Certifications: ISO 9001:2015, ISO 13485:2016, WHO-GMP, ISO 14001:2015, ISO 45001:2018, and medical devices conformity to 93/42/EEC medical directives
  • Credit Rating: CRISIL reaffirmed "BB+/Stable" and "A4+" ratings for banking facilities
  • Market Challenges: Faced oversupply, intensifying competition, and price pressures in the suture industry
  • R&D Focus: Development of new atraumatic needles and combinations of needles and sutures
  • Production Update: Started production of surgical threads; two new medical devices/codes under development and trials
  • Export Performance: Foreign exchange earnings of ₹300.08 lakhs (Previous Year: ₹140.04 lakhs)
  • Foreign Exchange Outgo: ₹466.11 lakhs (Previous Year: ₹734.40 lakhs)

Capital Structure Impact

  • No change in share capital during the year
  • No shares issued with differential voting rights, stock options, or sweat equity granted
  • 93.04% of equity shares (33,94,500 shares) were dematerialized as of March 31, 2026

Governance and Compliance

  • Board Composition: 7 Directors (1 Managing Director, 2 Executive Directors, 4 Independent Directors)
  • Board Meetings: 5 meetings held during the year with 100% attendance by all directors
  • Committee Meetings:
  • Audit Committee: 5 meetings
  • Nomination and Remuneration Committee: 1 meeting
  • Stakeholders Relationship Committee: 4 meetings
  • Compliance Status: Secretarial Audit Report contained no qualifications, reservations, or adverse remarks
  • Whistle Blower Policy: Implemented and available on company website
  • Related Party Transactions: All transactions were at arm's length and in ordinary course of business

Remuneration Details

  • Vijay Majrekar (MD/CEO): ₹268.80 lakhs
  • Devraj T. Poojary (Executive Director): ₹7.80 lakhs
  • Mahima Bathwal (Company Secretary): ₹2.46 lakhs
  • Anuradha Kashikar (Executive Director/CFO): Nil remuneration (voluntarily chose not to receive remuneration)
  • Independent Directors: Sitting fees of ₹0.50 lakhs each

Forward-looking Statements

The management discussion highlights expectations of continued challenges in the business environment but expresses confidence in the company's integrated capabilities and strategic priorities. The company anticipates stable demand over the medium-term but notes short-term volatility due to geopolitical uncertainty and costs.

Material Changes and Commitments

  • Preparation started for manufacturing surgical threads raw materials to reduce reliance on previous suppliers
  • No other material changes or commitments affecting the financial position occurred between year-end and report date

Legal and Regulatory Matters

  • No significant material orders passed by regulators, courts, or tribunals impacting going concern status
  • No proceedings initiated or pending under the Insolvency and Bankruptcy Code, 2016
  • Cost audit not applicable as company did not meet specified turnover criteria

Other Disclosures

  • Employee strength: 266 as of March 31, 2026
  • CSR provisions not applicable to the company
  • No deposits accepted from public
  • No frauds reported by auditors during the year
  • All properties and insurable interests fully insured

#Tags: #CentenialSurgical #AnnualReport #SEBIDisclosure #FinancialResults #MedicalDevices #RegulatoryCompliance #Negative